Drugs / Anastrozole
Anastrozole
also known as
ARIMIDEX · anastrazole · Arimidex (Anastrozole) · Anastrozole (Arimidex) · 120511-73-1, 2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile), Alpha,alpha,alpha', alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile, · ANA · Anastrazol · Anastrozol · +4 more
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (5) | US (FDA) | ARIMIDEX | — | 2000-09-01 – 2011-04-18 | fda.gov ↗ |
| Approved | US (FDA) | ARIMIDEX | — | 1995-12-27 | fda.gov ↗ |
Trials 205 · started per year
today
US approved 1995
3
1
1
1
2
4
2
6
10
11
7
11
10
1
8
5
6
5
10
9
12
11
6
9
9
4
10
5
9
9
7
199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05238831 | Jan 2023 → May 2026 | female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 124 trials | ||||||
| Phase 1 | NCT07604272 | Oct 2026 → Jul 2028 expected | hernia, double inguinal | Northwestern University | Recruiting | No outcome recorded |
| Phase 1 | NCT07163481 | Oct 2025 → Dec 2026 expected | female breast carcinoma | Hunan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04556773 | Dec 2020 → Aug 2023 overdue | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04757532 | Dec 2020 → Mar 2021 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1 | NCT03554044 | Feb 2020 → Dec 2023 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, invasive breast carcinoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT04188548 | Dec 2019 → Jun 2020 overdue | breast cancer, endometrial cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03959891 | May 2019 → Dec 2022 overdue | breast cancer | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03616587 | Oct 2018 → Sep 2024 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03314298 | Aug 2017 → Apr 2018 | breast disorder | Havah Therapeutics Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03099174 | May 2017 → May 2023 | breast neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03264651 | Feb 2017 → Mar 2018 | breast disorder | Havah Therapeutics Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02779751 | Nov 2016 → Feb 2020 overdue | breast cancer, non-small cell lung carcinoma | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02545452 | Sep 2015 → Mar 2016 | endometriosis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02093351 | Sep 2014 → Apr 2015 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02057133 | Mar 2014 → Mar 2021 overdue | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02026973 | Mar 2014 → Nov 2015 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01862835 | May 2013 → Sep 2016 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01344031 | Apr → Jul 2011 | estrogen-receptor positive breast cancer, invasive breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01197170 | Sep 2010 → Jan 2021 | cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03118479 | May → Sep 2010 | Kallmann syndrome | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT01155960 | May → Jun 2008 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01155947 | May → Jun 2008 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01182181 | Aug → Sep 2005 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00588003 | Mar 2004 → Nov 2009 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/25 trials · 1 met primary | ||||||
| Phase 1/2 | NCT03481998 | Mar 2018 → Jul 2022 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03304080 | Dec 2017 → Jul 2026 overdue | breast neoplasm | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02730923 | Apr 2016 → Nov 2019 | endometrial carcinoma, hormone receptor-positive breast cancer, metastatic carcinoma | Centre Leon Berard | Unknown | No outcome recorded |
| Phase 1/2 | NCT01484041 | Apr 2012 → Dec 2015 | breast cancer | Georgetown University | Terminated | No outcome recorded |
| Phase 1/2 | NCT01215292 | Jan 2011 → Mar 2012 | — | University of Washington | Completed | Met primary |
| Phase 2108 trials · 5 met primary · 6 missed | ||||||
| Phase 2 | NCT07826052 | Sep 2026 → Sep 2031 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07796880 | Sep 2026 → Sep 2028 expected | hormone receptor-positive breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07618923 | Jun 2026 → Jun 2028 expected | hormone receptor-positive breast cancer | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07527806 | May 2026 → May 2029 expected | breast cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07483307 | Mar 2026 → Mar 2030 expected | Her2-receptor negative breast cancer, breast lobular carcinoma, estrogen-receptor positive breast cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07179939 | Sep 2025 → Dec 2030 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06970912 | Aug 2025 → Dec 2029 expected | female breast carcinoma, hormone receptor-positive breast cancer | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06953882 | Jul 2025 → Sep 2030 expected | Her2-receptor negative breast cancer | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT07810088 | Jun 2025 → Jun 2028 expected | hormone receptor-positive breast cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT06361940 | Sep 2024 → Dec 2028 expected | breast cancer | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 2 | NCT06086704 | Sep 2024 → Aug 2028 expected | breast cancer | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 2 | NCT05837455 | May 2024 → Nov 2027 expected | breast cancer | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06957379 | Feb 2024 → Jun 2025 overdue | hormone receptor-positive breast cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06375707 | Jan 2024 → Nov 2025 | breast cancer | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05501704 | Oct 2023 → Apr 2027 expected | hormone receptor-positive breast cancer, male breast carcinoma | Jose Pablo Leone | Recruiting | No outcome recorded |
| Phase 2 | NCT06145308 | Aug 2023 → Jul 2028 expected | salivary gland carcinoma | Peking Union Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT05826964 | Jun 2023 → Jul 2026 overdue | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | University of Miami | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05190094 | Dec 2022 → Dec 2025 overdue | hormone receptor-positive breast cancer | International Cancer Research Group, United Arab Emirates | Recruiting | No outcome recorded |
| Phase 2 | NCT05297617 | Oct 2022 → Nov 2030 expected | breast cancer | UNICANCER | Recruiting | No outcome recorded |
| Phase 2 | NCT05411380 | Oct 2022 → Apr 2024 | breast cancer | wang shusen | Unknown | No outcome recorded |
| Phase 2 | NCT05640778 | Oct 2022 → Oct 2024 | luminal B breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT05467891 | Sep 2022 → Aug 2028 expected | hormone receptor-positive breast cancer | Oana Danciu | Recruiting | No outcome recorded |
| Phase 2 | NCT05524584 | Aug 2022 → Dec 2028 expected | hormone receptor-positive breast cancer | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 2 | NCT04886531 | Jul 2022 → Dec 2026 expected | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer, progesterone-receptor positive breast cancer | Ruth O'Regan | Recruiting | No outcome recorded |
| Phase 2 | NCT05150652 | Feb 2022 → Dec 2025 | Her2-receptor negative breast cancer | Irada Ibrahim-zada | Completed | No outcome recorded |
| Phase 2 | NCT04383275 | Aug 2021 → May 2025 overdue | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT04666961 | Feb 2021 → Aug 2024 overdue | ductal breast carcinoma in situ | Institut Cancerologie de l'Ouest | Recruiting | No outcome recorded |
| Phase 2 | NCT04719273 | Jan 2021 → Mar 2025 | endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial mixed adenocarcinoma, endometrial serous adenocarcinoma +1 | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 2 | NCT04569747 | Jan 2021 → Mar 2029 expected | HER2 positive breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04553770 | Oct 2020 → Dec 2026 expected | female breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04352777 | Sep 2020 → Jun 2025 | hormone receptor-positive breast cancer | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT04294225 | Apr 2020 → Dec 2022 | invasive breast carcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT04272801 | Apr 2020 → Jun 2024 overdue | female breast carcinoma | Shayna Showalter, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04227327 | Jan 2020 → Jul 2024 | breast cancer | University of Milano Bicocca | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04088110 | Nov 2019 → Nov 2021 | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer | Fuzhou General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04075604 | Oct 2019 → Jul 2021 | breast cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT04113863 | Jun 2019 → Jan 2025 | breast neoplasm | Mario Negri Institute for Pharmacological Research | Terminated | No outcome recorded |
| Phase 2 | NCT03909152 | May 2019 → Sep 2024 | endometrial endometrioid adenocarcinoma, ovarian granulosa cell tumor | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03839823 | Feb 2019 → Apr 2022 | breast cancer | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT03691493 | Feb 2019 → Oct 2022 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, metastatic carcinoma in the bone +1 | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT03944434 | Dec 2018 → Dec 2024 overdue | breast cancer | Fondazione Sandro Pitigliani | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03229499 | Dec 2017 → Jul 2022 | pulmonary arterial hypertension | University of Pennsylvania | Completed | Missed primary |
| Phase 2 | NCT03272477 | Oct 2017 → Jul 2020 | breast cancer | Palleos Healthcare GmbH | Completed | Met primary |
| Phase 2 | NCT03179904 | Aug 2017 → Jul 2024 | HER2 positive breast carcinoma, female breast carcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03211572 | Aug 2017 → Aug 2018 | breast cancer | Ottawa Hospital Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03219476 | Feb 2017 → Feb 2020 | invasive breast carcinoma | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 2 | NCT02476786 | Jan 2017 → Jan 2027 expected | breast cancer | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT02942355 | Dec 2016 → Jun 2028 expected | female breast carcinoma | Wake Forest University Health Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02894398 | Sep 2016 → Feb 2023 | hormone receptor-positive breast cancer | iOMEDICO AG | Completed | No outcome recorded |
| Phase 2 | NCT02689921 | Apr 2016 → Dec 2018 | breast neoplasm | Midwestern Regional Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02648477 | Mar 2016 → Apr 2022 | estrogen-receptor positive breast cancer, progesterone-receptor positive breast cancer, triple-negative breast carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02188745 | Mar 2016 → Jan 2024 | breast cancer | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03204734 | Jan 2016 → Dec 2020 | breast cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02910050 | Jan 2016 → Sep 2018 | breast cancer | Xu fei | Unknown | Missed primary |
| Phase 2 | NCT02585388 | Oct 2015 → May 2017 | breast cancer | ARCAGY/ GINECO GROUP | Terminated | No outcome recorded |
| Phase 2 | NCT02441946 | Aug 2015 → Aug 2016 | hormone receptor-positive breast cancer | Eli Lilly and Company | Completed | Met primary |
| Phase 2 | NCT02448420 | Jul 2015 → Sep 2023 | breast cancer | SOLTI Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 2 | NCT02440230 | May 2015 → Dec 2021 | breast cancer | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03933618 | Apr 2015 → Mar 2017 | hypogonadism, male | Albany Medical College | Completed | No outcome recorded |
| Phase 2 | NCT02603679 | Feb 2015 → Jul 2021 overdue | estrogen-receptor positive breast cancer | Thomas Hatschek | Active not recruiting | Missed primary |
| Phase 2 | NCT02203331 | Oct 2014 → Oct 2016 | endometriosis | Bayer | Completed | Missed primary |
| Phase 2 | NCT02140437 | Mar 2014 → Dec 2015 | breast carcinoma | Fudan University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02000596 | Jan 2014 → Nov 2015 | breast cancer | University of Maryland, Baltimore | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01989780 | Jan 2014 → Jun 2018 | breast cancer | Japan Breast Cancer Research Group | Completed | Met primary |
| Phase 2 | NCT01776008 | Jan 2013 → May 2015 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01545336 | Oct 2012 → Jun 2015 | pulmonary arterial hypertension | University of Pennsylvania | Completed | Mixed |
| Phase 2 | NCT01972984 | Oct 2012 → Aug 2014 | breast cancer | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02549430 | Oct 2012 → Feb 2017 | breast cancer | Fondazione Sandro Pitigliani | Completed | No outcome recorded |
| Phase 2 | NCT01368263 | Sep 2011 → May 2013 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01394211 | Jul 2011 → Apr 2012 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, male breast carcinoma | University of Arizona | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01266213 | Dec 2010 → Jun 2018 | estrogen-receptor positive breast cancer | Samsung Medical Center | Unknown | Met primary |
| Phase 2 | NCT01234532 | Oct 2010 → May 2017 | female breast carcinoma, triple-negative breast carcinoma | University of Maryland, Baltimore | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01924078 | Oct 2010 → Mar 2015 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT00932152 | Sep 2010 → Jan 2013 | non-small cell lung carcinoma | University of Pittsburgh | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01151215 | Jun 2010 → Jan 2013 | breast cancer | AstraZeneca | Terminated | Missed primary |
| Phase 2 | NCT00729859 | Dec 2008 → May 2010 | — | University of Washington | Completed | Missed primary |
| Phase 2 | NCT00687648 | May 2008 → Apr 2010 | female breast carcinoma | National Cancer Centre, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT00661531 | Apr 2008 → Jun 2015 | breast cancer | Georgetown University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00481845 | Jan 2008 → Dec 2009 | breast cancer | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00629616 | Oct 2007 → Jun 2015 | breast cancer | UNICANCER | Completed | No outcome recorded |
| Phase 2 | NCT00555477 | Aug 2007 → Dec 2011 | female breast carcinoma | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00437359 | May 2007 → May 2017 | breast neoplasm | Japan Breast Cancer Research Network | Terminated | No outcome recorded |
| Phase 2 | NCT00467493 | Mar → Sep 2007 | menstrual disorder | Meditrina Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00405938 | Nov 2006 → Jun 2010 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00354640 | Jun 2006 → Oct 2008 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00382057 | May 2006 → Mar 2011 | metabolic syndrome X | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Withdrawn | No outcome recorded |
| Phase 2 | NCT00357110 | Apr 2006 → Oct 2008 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00217659 | Sep 2005 → Jan 2007 | breast cancer | SWOG Cancer Research Network | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00303615 | Jun 2005 → Jun 2007 | breast cancer | Legacy Health System | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00241436 | Jun 2005 → Nov 2006 | gynecomastia disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00213148 | Mar 2005 → Dec 2007 | anovulation | EMD Serono | Completed | No outcome recorded |
| Phase 2 | NCT00094328 | Nov 2004 → May 2008 | precocious puberty | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00136695 | Oct 2004 → Oct 2008 | hypogonadism | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00256217 | Sep 2004 → Dec 2018 | ductal breast carcinoma in situ | Rita Sanghvi, Mehta | Completed | No outcome recorded |
| Phase 2 | NCT00104572 | Mar 2004 → Dec 2013 | depressive disorder, diabetes mellitus, hypogonadism, muscular atrophy +1 | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 2 | NCT00244959 | Jan 2004 → Sep 2007 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00255463 | Jan 2004 → Nov 2005 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00081510 | Dec 2003 → May 2009 | breast cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00181688 | Oct 2003 → Mar 2006 | fallopian tube cancer, ovarian cancer, peritoneal carcinoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00057941 | Sep 2003 → Jun 2012 | estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00049062 | Sep 2002 → Oct 2007 | breast cancer | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 2 | NCT00055302 | Aug 2002 → Feb 2006 | McCune-Albright syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00235937 | Dec 2001 → Dec 2006 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00128843 | Aug 2001 → Jul 2005 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 2 | NCT00179517 | Jun 2001 → Apr 2008 | epilepsy, erectile dysfunction, hypogonadism | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00186121 | Oct 2000 → May 2013 | breast cancer | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00004906 | Oct 1999 → Jun 2001 | breast cancer | Hackensack Meridian Health | Completed | No outcome recorded |
| Phase 2 | NCT00287534 | Nov 1996 → Sep 2004 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 340 trials · 3 met primary · 7 missed | ||||||
| Phase 3 | NCT07153757 | Sep 2025 → Sep 2033 expected | female breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07005557 | Jun 2025 → May 2030 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06223698 | May 2025 → May 2032 expected | breast cancer | Region Örebro County | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06492616 | Sep 2024 → Aug 2029 expected | breast cancer | Stemline Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06380751 | Aug 2024 → Dec 2029 expected | breast cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06507618 | Jul 2024 → Jun 2029 expected | female breast carcinoma | University of Virginia | Recruiting | No outcome recorded |
| Phase 3 | NCT05586802 | Mar 2023 → Apr 2027 expected | Klinefelter syndrome | Georgios Papadakis | Recruiting | No outcome recorded |
| Phase 3 | NCT04158362 | Jun 2020 → Apr 2025 overdue | metastatic malignant neoplasm | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03079011 | Mar 2017 → Apr 2021 | breast cancer | UNICANCER | Completed | Met primary |
| Phase 3 | NCT02532400 | Mar 2016 → Mar 2019 | breast cancer | Ruijin Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02730091 | Feb 2016 → Mar 2020 | breast cancer | Centre Hospitalier Universitaire de Besancon | Terminated | No outcome recorded |
| Phase 3 | NCT02344472 | Sep 2015 → Jan 2025 | breast cancer | University of Ulm | Unknown | No outcome recorded |
| Phase 3 | NCT02535221 | Jul 2015 → Jun 2026 overdue | breast cancer | Peking University | Recruiting | No outcome recorded |
| Phase 3 | NCT02137837 | May 2014 → Dec 2019 | breast cancer | SWOG Cancer Research Network | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02097459 | Mar 2014 → Mar 2024 | breast cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01950182 | Sep 2013 → May 2020 | breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02918084 | Jun 2013 → Jun 2028 expected | breast cancer | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00893061 | Mar 2009 → Apr 2012 | breast cancer | Centre Oscar Lambret | Completed | No outcome recorded |
| Phase 3 | NCT00944918 | Dec 2008 → Jun 2011 | — | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT02338310 | Sep 2008 → Apr 2024 overdue | breast cancer | Institute of Cancer Research, United Kingdom | Active not recruiting | Missed primary |
| Phase 3 | NCT01352091 | May 2008 → May 2015 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT00902954 | Mar 2008 → Jun 2010 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT00543127 | Nov 2007 → Jul 2016 | breast cancer | Spanish Breast Cancer Research Group | Terminated | Missed primary Stop: Business |
| Phase 3 | NCT00605267 | Oct 2007 → Nov 2009 | breast cancer | AstraZeneca | Completed | Met primary |
| Phase 3 | NCT00541086 | Mar 2007 → Jul 2020 | breast cancer | Gruppo Italiano Mammella (GIM) | Unknown | Missed primary |
| Phase 3 | NCT00440180 | Mar 2007 → Jun 2014 | obesity disorder, oligospermia | University of Utah | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00301457 | Jun 2006 → Apr 2022 | breast cancer | Maastricht University Medical Center | Completed | Missed primary |
| Phase 3 | NCT00265759 | Jan 2006 → Aug 2012 | breast cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00327769 | Nov 2005 → Sep 2007 | female breast carcinoma | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT00143390 | Apr 2005 → Dec 2010 | breast neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00075764 | Apr 2004 → Dec 2012 | breast cancer | SWOG Cancer Research Network | Completed | Met primary |
| Phase 3 | NCT00295620 | Mar 2004 → Jun 2017 | breast cancer | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT00078832 | Sep 2003 → Dec 2013 | breast cancer | Queen Mary University of London | Completed | No outcome recorded |
| Phase 3 | NCT00053898 | Jan 2003 → Mar 2015 | breast cancer | NSABP Foundation Inc | Completed | No outcome recorded |
| Phase 3 | NCT00637182 | Jan 2001 → Jun 2002 | gynecomastia disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00232661 | Aug 2000 → Jan 2003 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00286117 | Mar 1998 → May 2006 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00635713 | May 1997 → Sep 2004 | female breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00300508 | Jan 1996 → ? | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00291759 | Jan 1996 → Jun 2009 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 416 trials · 1 missed | ||||||
| Phase 4 | NCT05362760 | Apr 2022 → Apr 2029 expected | hormone receptor-positive breast cancer | University of Ulm | Recruiting | No outcome recorded |
| Phase 4 | NCT03948568 | Sep 2019 → Jun 2021 | female breast carcinoma | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03238703 | Sep 2018 → Mar 2023 | Her2-receptor negative breast cancer, breast carcinoma in situ, female breast carcinoma, invasive breast carcinoma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03111615 | May 2018 → May 2019 | female breast carcinoma | Centro Hospitalar Lisboa Ocidental | Unknown | No outcome recorded |
| Phase 4 | NCT03490513 | Apr 2018 → May 2025 | hypogonadotropic hypogonadism, obesity disorder | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02959853 | Jun 2016 → Nov 2018 | hypogonadism, morbid obesity | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02089854 | Nov 2014 → Apr 2019 | breast cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01553903 | Dec 2011 → May 2013 | breast cancer | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 4 | NCT01127295 | Jun 2010 → Dec 2017 | hormone receptor-positive breast cancer | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 4 | NCT00537771 | Sep 2007 → Dec 2011 | breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00323479 | Jun 2006 → Jan 2009 | female breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00126360 | Aug 2005 → May 2016 | breast cancer | St George Hospital, Australia | Unknown | No outcome recorded |
| Phase 4 | NCT00544986 | Jun 2005 → Nov 2007 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00286351 | Jan 2005 → ? | endometriosis | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT00082277 | Apr 2004 → Oct 2007 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00286364 | — | infertility disorder | Rigshospitalet, Denmark | Completed | Missed primary |
| Phase not applicable11 trials | ||||||
| — | NCT07212712 | Apr → Dec 2026 expected | vascular disorder | University of British Columbia | Not yet recruiting | No outcome recorded |
| — | NCT06810492 | Apr → Dec 2025 overdue | female breast carcinoma | Hongmei Zheng, PhD | Not yet recruiting | No outcome recorded |
| — | NCT06235931 | Feb 2024 → Dec 2025 overdue | breast neoplasm | Second Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| — | NCT05167643 | Jan → Oct 2022 | Her2-receptor negative breast cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT01824836 | Jun 2013 → Jun 2022 overdue | estrogen-receptor positive breast cancer, female breast carcinoma, musculoskeletal system disorder, progesterone-receptor positive breast cancer | ECOG-ACRIN Cancer Research Group | Active not recruiting | No outcome recorded |
| — | NCT01720602 | Nov 2012 → Mar 2015 | male breast carcinoma | University of Washington | Completed | No outcome recorded |
| — | NCT01520467 | Apr 2012 → Jul 2016 | Prader-Willi syndrome, Silver-Russell syndrome | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| — | NCT00612560 | Nov 2007 → Jan 2011 | breast cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
| — | NCT01004744 | Jul 2007 → Aug 2009 | invasive breast carcinoma | Columbia University | Completed | No outcome recorded |
| — | NCT01016665 | Apr 2005 → Jul 2007 | breast cancer | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT00437853 | Jun 2003 → Feb 2007 | breast cancer | National Cancer Institute of Mexico | Completed | No outcome recorded |
| Comparator or background therapy161 trials | ||||||
| Phase 0 | NCT04088032 Background | Oct 2019 → Dec 2020 | female breast carcinoma, hormone receptor-positive breast cancer | Alison Stopeck | Withdrawn | No outcome recorded |
| Phase 0 | NCT01763541 Background | Jun 2014 → Feb 2016 | hypertensive disorder | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 1 | NCT06218303 Background | Feb 2024 → Aug 2026 overdue | ductal breast carcinoma in situ | Finn, Olivera, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT05307705 Background | May 2022 → Dec 2026 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT03846583 Background | Jun → Sep 2020 | breast cancer | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| Show all 161 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2026-09-11 | Alexion Pharmaceuticals, Inc. | Results Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer astrazeneca.com ↗
The trial evaluated the Etcamah combination versus treatment with an aromatase inhibitor (anastrozole) in combination with palbociclib. |
| 2026-06-02 | AstraZeneca | Results Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 trial astrazeneca.com ↗
Median PFS2 was 25.7 months for the camizestrant combination compared with 19.1 months for the AI combination. |
| 2025-06-01 | AstraZeneca | Results Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial astrazeneca.com ↗
Results showed the camizestrant combination reduced the risk of disease progression or death by 56% compared to standard-of-care treatment (based on a hazard ratio [HR] of 0.44; 95% confidence interval [CI] 0.31–0.60; p<0.00001) as assessed by investigator. |
| 2025-02-26 | AstraZeneca | Results Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial astrazeneca.com ↗ |
| 2023-12-05 | Eli Lilly and Company | Results Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium lilly.com ↗
For women with visceral organ metastases, data showed a median OS of more than five years, with an increase in median OS of 14.9 months in the Verzenio arm compared to the control arm (63.7 vs 48.8 months). |
| 2017-10-06 | Eli Lilly and Company | Results Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ (abemaciclib) Plus NSAI in Advanced Breast Cancer lilly.com ↗
MONARCH 3 met a rigorous threshold for demonstrating efficacy at the time of pre-planned interim analysis with a 46 percent reduction in the risk of progression or death in patients receiving initial therapy for metastatic disease. |
| 2017-08-24 | Novartis Pharmaceuticals | Regulatory Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor novartis.com ↗ |
| 2017-06-23 | Novartis Pharmaceuticals | Regulatory Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor novartis.com ↗
The CHMP recommendation of combining Kisqali with any aromatase inhibitor means that, if approved, oncologists could prescribe Kisqali with letrozole, anastrozole or exemestane, giving them the discretion to select the therapy they believe is most appropriate for each individual patient. |
| 2017-06-23 | AstraZeneca | Results Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer astrazeneca.com ↗
The median PFS was 16.6 months in the Faslodex arm compared with 13.8 months in the anastrozole arm. |
| 2017-04-24 | Eli Lilly and Company | Results Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis lilly.com ↗
INDIANAPOLIS, April 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint of demonstrating statistically significant improvement in progression-free survival (PFS). |
| 2016-12-08 | Eli Lilly and Company | Results Lilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer lilly.com ↗
The results showed that abemaciclib monotherapy and abemaciclib in combination with anastrozole significantly reduced Ki67 more than anastrozole alone. |
| 2016-09-30 | AstraZeneca | Results AstraZeneca presents new data on Faslodex in breast cancer and provides immuno-oncology update at ESMO 2016 congress astrazeneca.com ↗
Phase III FALCON trial demonstrates superiority of Faslodex over Arimidex in the 1st-line treatment of hormone-receptor positive (HR+) advanced breast cancer |
| 2016-05-27 | AstraZeneca | Results AstraZeneca’s Faslodex met primary endpoint in first-line treatment of advanced breast cancer astrazeneca.com ↗
Faslodex 500mg demonstrated superiority compared with Arimidex 1mg in FALCON, and met its primary endpoint of extended progression-free survival. |
| 2010-06-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Launch of Generic ARIMIDEX® tevapharm.com ↗
Jerusalem, June 28, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today U.S. Food and Drug Administration (FDA) approval and commercial launch of Anastrozole Tablets 1 mg, the Company's generic version of AstraZeneca's ARIMIDEX®. |
All press releases naming this drug 15 releases
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 372 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anastrozole | “POETIC was an open-label, multicentre, parallel-group, randomised, phase 3 trial (done in 130 UK hospitals) in which postmenopausal women aged at least 50 years with WHO...” PMID 33152284 ↗ Nov 2020360“Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or...” NCT03820830 ↗ “The experimental arm receives ribociclib at the standard dose (orally, 400mg, once daily on days 1-21 of a 28-day cycle) combined with a specified endocrine therapy (e.g.,...” NCT07380646 ↗ “aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone...” NCT04012918 ↗ “The premenopausal cohort assessed the efficacy and safety of treatment with a non-steroidal aromatase inhibitor (NSAI; letrozole or anastrozole) combined with goserelin and...” NCT03671330 ↗ “Options include tamoxifen (20 mg daily), aromatase inhibitors (letrozole 2.5 mg daily, anastrozole 1 mg daily, or exemestane 25 mg daily), or fulvestrant (500 mg...” NCT07708194 ↗ “Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and...” NCT02203331 ↗ “Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of...” NCT01446159 ↗ “Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or...” NCT03204734 ↗ “Letrozole：2.5mg，q4w or Anastrozole：1mg，q4w or Exemestane：25mg，q4w or Fulvestrant:Patients will receive intramuscular Fulvestrant on day 1 and day 15 of the first cycle and then...” NCT07810088 ↗ “Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be...” NCT03184090 ↗ |
| Known as | 120511-73-1, 2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile), Alpha,alpha,alpha', alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile, | “120511-73-1, 2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile), Alpha,alpha,alpha',...” NCT04719273 ↗ |
| Known as | ANA | “anastrozole (ANA) in combination with/without metronomic tegafur-uracil (UFT)” NCT01262274 ↗ |
| Known as | Anastrazol | “Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.” NCT03111615 ↗ |
| Known as | anastrazole | “Aromatase inhibitors such as anastrazole are establishing themselves as a class of drug superior to tamoxifen for the control of estrogen dependent breast cancers and overall...” NCT00126360 ↗6“Aromatase inhibitors (AI) (Anastrazole) and selective estrogen receptor modifiers (SERMS)(clomiphene) increase testosterone production through stimulation of the hypothalamic...” NCT03933618 ↗ “Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients...” NCT03671330 ↗ “Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent” NCT02959853 ↗ “With 1mg Arimidex (Anastrazole) in Postmenopausal Women With Advanced Breast Cancer.” NCT00635713 ↗ “ARIMIDEX (anastrazole)” NCT00232661 ↗ “Anastrazole (Arimidex)” NCT00605267 ↗ |
| Known as | Anastrozol | “Arimidex® (Anastrozol)” NCT00295620 ↗ |
| Known as | Anastrozole (Arimidex) | “Anastrozole (Arimidex)” NCT02000596 ↗1“Anastrozole (Arimidex)” NCT06218303 ↗ |
| Known as | Anastrozole Tablets | “Drug: Anastrozole Tablets” NCT04906395 ↗ |
| Known as | ARIMIDEX | “An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With...” NCT00066378 ↗22“The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.” PMID 10873072 ↗ Jun 2000 “Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment” NCT01602380 ↗ “Comparing the Anastrozole (Arimidex®) Placebo Combination to the Anastrozole - ZD1839 (Iressa™) Combination” NCT00255463 ↗ “Endocrine Therapy: Exemestane (Aromasin®), Letrozole (Femara®), or Anastrozole (Arimidex®)” NCT03846583 ↗ “With 1mg Arimidex (Anastrazole) in Postmenopausal Women With Advanced Breast Cancer.” NCT00635713 ↗ “Arimidex® (anastrozole) 1 mg/day by mouth (PO)” NCT00828854 ↗ “Anastrozole 10 mg (Arimidex) orally daily” NCT00438321 ↗ “Anastrozole (Arimidex) 1 mg orally QD” NCT00932152 ↗ “Drug: Anastrozole (Arimidex)” NCT07212712 ↗ “Anastrozole (ARIMIDEX™)” NCT07604272 ↗ |
| Known as | Arimidex (Anastrozole) | “Arimidex (Anastrozole)” NCT01248416 ↗ |
| Known as | ATZ | “intra-vaginal ring (IVR) releasing anastrozole (ATZ) and levonorgestrel (LNG)” NCT02545452 ↗ |
| Known as | NSC #719344 | “Combination Anastrozole (NSC #719344) Plus ZD1839” NCT00057941 ↗ |
| Known as | ZD1033 | “Comparing Anastrozole (ZD1033, Arimidex™)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSA™) in Postmenopausal Patients With Estrogen Receptor (ER) and/or...” NCT00077025 ↗ |
| Action | Inhibit | “Arimidex® (Anastrozole) an Aromatase Inhibitor” NCT00022672 ↗ |
| Modality | Other / unclassified | “Anastrozole (Arimidex®) and Letrozole (Femara®) are AIs” NCT02095184 ↗ |
| Route | Oral | “patients receive oral anastrazole daily until disease progression” NCT00004900 ↗ |